1. Introduction {#sec1}
===============

The prevalence of hepatitis C virus (HCV) has been estimated to be 3% throughout the world. The severity of the disease is dependent on the extension of hepatic fibrosis. Liver biopsy is currently considered as the gold standard for determination of the grade of fibrosis \[[@B1]\]. Presence of significant fibrosis (F2--4) is accepted as the treatment indication \[[@B2], [@B3]\]. Liver biopsy is unfortunately associated with many complications for patients, including pain, bleeding, and rarely death, high costs, variations in diagnosis of histological grades, and sampling errors \[[@B4]\]. Furthermore, liver biopsy can provide only a view of a static or dynamic disease, and multiple biopsies are required to determine the disease progression or recurrence of fibrosis. This reveals the need for noninvasive, precise, and valid methods \[[@B5]\].Considerable advances have occurred in identification of nonspecific fibrosis biomarkers. The nonspecific markers include age, gender, and laboratory markers of liver damage or dysfunction (AST, ALT, *γ*-glutamyl transferase (GGT), bilirubin, hapatoglobin, platelet count, and prothrombin time), while metabolic markers are cholesterol, apoprotein A1 (Apo A1), and *α*2-macroglobulin (A2M).

So far, the index of ratio of AST to platelet count (APRI) has been the simplest test using nonspecific markers, which is valuable in predicting fibrosis \[[@B6]--[@B9]\].

The fibrometer test, which includes hyaluronic acid (HA), PT test, platelet count, AST, A2M, urea, and age, is to some extent efficient. Another achievement was the use of specific fibrosis biomarkers such as HA, matrix metalloproteinase 2, tissue inhibitor of matrix metalloproteinase 1, and amino-terminal peptide of type III procollagen \[[@B1], [@B10]\]. When used in combination with each other, it is known that these markers are valid in determining the liver fibrosis score \[[@B11]\]. Recently, some attempts have been performed to improve the nonspecific indices by use of fibrosis-specific markers. Adams et al. suggested Hepascore, which is a combination of HA, total bilirubin, GGT, A2M, age, and gender \[[@B12]\]. Hepascore was shown to be valid in the HCV population in Australia and then in two other groups in a European country (France) \[[@B12]--[@B14]\]. The aim of the current study is to compare the results of liver biopsy of patients with hepatitis C, genotype 1, in Isfahan with their Hepascore, and also to determine sensitivity, specificity, and positive and negative predictive values of Hepascore.

2. Materials and Methods {#sec2}
========================

The participants were in the age range of 18--65, with the mean age of 35.3 ± 12.7. Out of the participants, 68 patients (85%) were males.

Among the patients with hepatitis C, genotype 1, who referred to the GI clinic or ward of Alzahra Hospital from April to October 2010 and met the inclusion criteria of the study, 80 patients were included in the study using nonrandom simple method. The inclusion criteria were the newly diagnosed patients of hepatitis C, genotype 1, who were candidates of liver biopsy. If the patients were not willing to participate in the study, they were excluded.

2.1. Liver Biopsy {#sec2.1}
-----------------

All liver biopsies were taken under supervision of a hepatology subspecialist using an 18-gauge Menghini needle or a 16-gauge Trucut needle, with the size of ≥10 mm. The specimens were then evaluated by a single skilled pathologist for the degree of fibrosis according to the METAVIRE classification \[[@B1]\].

The degree of fibrosis was classified in a 0--4 scale as follows: F0: no fibrosis, F1: portal fibrosis alone, F2: portal fibrosis with rare septae, F3: portal fibrosis with many septae, and F4: cirrhosis. Grades F2, F3, and F4 indicate significant fibrosis, F3 and F4 show severe fibrosis, and F4 indicates cirrhosis.

2.2. Blood Samples {#sec2.2}
------------------

From all the participants, a 10 mL blood sample was obtained, and its serum was kept at −70°C. Determination of serum level of hyaluronic acid (Corgenix, USA), GGT (Biosystems, Spain), and A2M (Immundiagnostik, German) was performed using enzyme-linked protein binding assay, and the level of total bilirubin was determined using Biosystem A15 Autoanalyzer with specific reagents.

2.3. Calculation of Hepascore {#sec2.3}
-----------------------------

To calculate the Hepascore, the values obtained for the four biomarkers, A2M, GGT, total bilirubin, and HA, and the age and gender of the patient are set in the following formula, which was first issued by Adam et al. \[[@B12]\] in 2005:

$$\begin{aligned}
Y & {= \text{EXP}\left( {- 4.185818 - \left( {0.0249\,\ast\,\text{age}} \right){\,\,}{\,\,}} \right.{\,\,}} \\
 & {\quad\quad\quad\quad + \left( {0.7464\,\ast\,\text{sex}} \right) + \left( {1.0039\,\ast\,\text{A}2\text{M}} \right)} \\
 & {\quad\quad\quad\quad + \left( {0.0302\,\ast\,\text{HA}} \right) + \left( {0.0691\,\ast\,\text{Bil-t}} \right)} \\
 & {{\,\,}\quad\quad\quad\quad\left. {{\,\,} - \left( {0.0012\ast\,\text{GGT}} \right)} \right),} \\
 & {\text{Hepascore} = \frac{Y}{\left( {1 + Y} \right)}.} \\
\end{aligned}$$ The value for sex in the above formula is 1 for men and 0 for women.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All data was analyzed in the SPSS software, using rho Spearman and ROC analysis. The *P* values below 0.05 were considered to be statistically significant.

3. Results {#sec3}
==========

The range of variation, mean, and standard deviation values for HA, A2M, GGT, and bilirubin is provided in [Table 1](#tab1){ref-type="table"}.

3.1. Liver Histology {#sec3.1}
--------------------

The results of liver biopsy for the patients were as follows: 12 patients were F0, 25 were patients F1, 20 were patients F2, seven patients were F3, and 16 patients were F4. The frequency distribution for fibrosis severity according to the biopsy results is demonstrated in [Table 2](#tab2){ref-type="table"}.

3.2. Hepascore of Patients {#sec3.2}
--------------------------

Mean and median of Hepascore in different degrees of fibrosis (according to biopsy) are shown in Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, respectively.

Correlation between Hepascore and Biopsy ResultsAccording to the results obtained from Spearman\'s correlation test, there is a relatively strong correlation between severity of fibrosis estimated by Hepascore and that determined by liver biopsy (*r* = 0.465, *P* = 0.003).

3.3. Sensitivity, Specificity, and Positive and Negative Predictive Values of Hepascore {#sec3.3}
---------------------------------------------------------------------------------------

Sensitivity and specificity of Hepascore in diagnosis of significant fibrosis (F2, F3, and F4 from F0 and F1) in different cut-off points are shown in [Figure 2](#fig2){ref-type="fig"}. In cut-off point 0.34, sensitivity, specificity, PPV, and NPV were 67%, 56%, 64%, and 56%, respectively.

Sensitivity and specificity of Hepascore in diagnosis of severe fibrosis (F3 and F4 from F0, F1, and F2) in different cut-off points are demonstrated in [Figure 3](#fig3){ref-type="fig"}. In point 0.61, sensitivity, specificity, PPV, and NPV were 82%, 86%, 70%, and 92%, respectively.

Sensitivity and specificity of Hepascore in diagnosis of cirrhosis (F4 from F0, F1, F2, and F3) in different cut-off points are shown in [Figure 4](#fig4){ref-type="fig"}. In point 0.84, sensitivity, specificity, PPV, and NPV were 100%, 97%, 89%, and 100%, respectively.

4. Discussion {#sec4}
=============

Prognosis of chronic liver diseases is strongly correlated with the degree of liver fibrosis. In chronic hepatitis C, besides having prognostic value, liver fibrosis is related to the therapeutic approach \[[@B15]\]. So far, no FDA-approved noninvasive method has been proposed for determination of liver fibrosis. A suggested and growing method is determination of Hepascore of the patients on the basis of blood markers of fibrosis. The current study demonstrated that Hepascore index has a reasonable sensitivity, specificity, NPV, and PPV. According to the results obtained, from among the cut-off points between 0 and 1, the most appropriate point for diagnosis of significant fibrosis from mild fibrosis and no fibrosis (F0 and F1) was 0.34. In other studies, cut-off points from 0.32 to 0.55 were obtained \[[@B1], [@B12], [@B14]--[@B16]\].

The authors who devised Hepascore \[[@B10]\] and also Adams et al. \[[@B12]\] methods suggested cut-off point 0.5. Becker et al. suggested point 0.55 as the most appropriate cut-off point \[[@B1]\], while Leroy et al. obtained cut-off point 0.32 \[[@B16]\] ([Table 3](#tab3){ref-type="table"}).

Considering the above-mentioned points, the sensitivity of Hepascore in diagnosis of significant fibrosis was obtained to be point 67%. The value was reported to be from 54% to 82% \[[@B1], [@B12], [@B14]\]. Moreover, the specificity of the method was determined to be 56%, which was reported to be from 63% to 89% in previously performed studies \[[@B1], [@B10], [@B12], [@B16], [@B17]\]. The PPV and NPV of the test in diagnosis of significant fibrosis were determined to be 64% and 56%, respectively. In previous studies, the values were determined to be 59% to 89% and 64% to 80%, respectively \[[@B1], [@B14]\].

According to the results obtained, the most appropriate point for diagnosis of severe fibrosis from milder forms of fibrosis was determined to be 0.61, and the sensitivity and specificity were 82% and 86%, respectively. The appropriate cut-off points for this purpose were determined to be from 0.53 to 0.84 in previous studies.

We obtained the most appropriate cut-off point for diagnosis of cirrhosis for milder forms of fibrosis to be 0.84. At this cut-off point, sensitivity, specificity, PPV, and NPV were determined to be 100%, 97%, 89%, and 100%, respectively. Adams et al. \[[@B12]\] determined sensitivity and specificity of Hepascore in diagnosis of cirrhosis to be 71% and 84%, respectively. Guéchot et al. reported the sensitivity, specificity, PPV, and NPV of the test in diagnosis of cirrhosis to be 86%, 74%, 37%, and 97%, respectively. In spite of the differences among the values obtained in different studies, the high sensitivity and NPV were noteworthy in all the studies. The values obtained for these items were 100% in the current study. Therefore, using Hepascore, one can surely make decision on performance of screening for hepatocellular carcinoma, as well as carrying out endoscopy for evaluation of esophageal varicosis, both of which are currently rather high-cost and invasive procedures.

A factor that affects the above-mentioned elements is the difference in frequency distribution of severity of fibrosis in different studies. For instance, the prevalence of significant fibrosis in the current study was 53.8%, while the rate was reported to be 44% to 51% in other studies. Another cause for the differences is the errors in pathological interpretations and laboratory error. Nevertheless, since in clinical settings the aim of evaluation of these patients is detection of significant fibrosis to initiate the treatment, higher sensitivity of the test is of great importance.

As can be observed in [Table 3](#tab3){ref-type="table"}, the findings of the current study are to a great extent consistent with other studies with regard to the relative weakness of Hepascore in diagnosis of lower stages of fibrosis and its high power in diagnosis of high stages of fibrosis. However, compared with previously performed studies, the cut-off point determined in the current study has a higher sensitivity and specificity for diagnosis of severe fibrosis and cirrhosis.

5. Conclusion {#sec5}
=============

Hepascore is highly valuable in diagnosis of the severity of liver fibrosis and particularly cirrhosis (F4) and can be used as a primary screening method for diagnosis of the need for carrying out liver biopsy, which is a method with high costs and complications.

One of the limitations of the study was its small sample size, which was due to the economic constraints. With respect to the promising results obtained, similar study on a larger population can be performed.

![(a) Relationship between mean of Hepascore and severity of liver fibrosis. (b) Relationship between median of Hepascore and severity of liver fibrosis.](HEPRT2011-972759.001){#fig1}

![ROC curve of predictive value in significant liver fibrosis.](HEPRT2011-972759.002){#fig2}

![ROC curve of predictive value in diagnosis of severe fibrosis.](HEPRT2011-972759.003){#fig3}

![ROC curve of predictive value in diagnosis of cirrhosis.](HEPRT2011-972759.004){#fig4}

###### 

Range of variation for independent variables.

  Variable                                    Marker                                      
  -------------------------- ---------------- -------------- -------------- ------------- -------------
  Age group\*                18--20 yr        34.7 ± 5.3     60 ± 10.9      32.9 ± 4.9    2.1 ± 0.15
  27--31 yr                  23.6 ± 2.8       43 ± 4         15.3 ± 0.67    1.4 ± 0.12    
  32--46 yr                  21.8 ± 4.6       51.6 ± 6.2     15 ± 1.3       1.9 ± 0.2     
  47--65 yr                  96.1 ± 31.3      59.3 ± 7       16.5 ± 1.5     3.4 ± 0.2     
  *P* value for age\*\*                       0.003\*\*      0.42           \<0.001\*\*   \<0.001\*\*
                                                                                          
  Sex\*\*\*                  Male             29 ± 3.34      56 ± 4.6       18.5 ± 1      2.1 ± 0.12
  Female                     125.95 ± 46.33   41.6 ± 4.2     32.2 ± 9.6     3 ± 0.37      
  *P* value for sex\*\*                       \<0.001\*\*    0.19           0.004\*       0.004\*
                                                                                          
  Biopsy\*                   F0               31.5 ± 7       44.9 ± 7.1     31.5 ± 8.9    1.7 ± 0.1
  F1                         16.25 ± 2.2      39.25 ± 5.4    18.8 ± 1.1     1.8 ± 0.19    
  F2                         26.16 ± 4.5      68.24 ± 8.8    13.27 ± 0.93   2 ± 0.24      
  F3                         30.6 ± 4.8       32.33 ± 3.1    11.9 ± 1.6     2.5 ± 0.52    
  F4                         121.97 ± 34.5    72.62 ± 10.2   27 ± 1.7       3.4 ± 0.14    
  *P* value for biopsy\*\*                    \<0.001\*\*    0.003\*\*      0.002\*\*     \<0.001\*\*

\*Performed by one-way ANOVA.

\*\*Significant at 0.05.

\*\*\*Performed by independent  *t*-test.

###### 

Frequency distribution for fibrosis severity according to the biopsy results.

  Severity of fibrosis   No. of patients   \%
  ---------------------- ----------------- -------
  F0                     12                15
  F1                     25                31.25
  F2                     20                25
  F3                     7                 8.75
  F4                     16                20

###### 

Comparison of cut-off points, sensitivity, specificity, PPV, and NPV in different studies.

                               Adams et al. \[[@B12]\]   Leroy et al. \[[@B16]\]   Halfon et al. \[[@B17]\]   Becker et al. \[[@B1]\]   Guechot et al. \[[@B14]\]   This study
  ---------------------------- ------------------------- ------------------------- -------------------------- ------------------------- --------------------------- ---------------
  Patients number              104                       180                       356                        391                       512                         80
  F0/F1/F2/F3/F4 (%)           16/27/34/7/16             8/41/22/14/14             4/55/26/11/4               16/34/15/16/19            7/45/18/15/15               15/31/25/8/20
                                                                                                                                                                    
  For significant fibrosis                                                                                                                                          
   Cut-off                     0.5                       0.5                       0.32                       0.55                      0.5                         0.34
   Sensitivity                 63%                       54%                       77%                        82%                       77%                         67%
   Specificity                 89%                       84%                       63%                        65%                       70%                         56%
   Positive predictive value   /                         78%                       59%                        70%                       71%                         64%
   Negative predictive value   /                         64%                       80%                        78%                       77%                         56%
                                                                                                                                                                    
  For sever fibrosis                                                                                                                                                
   Cut-off                     /                         0.84                      0.53                       0.8                       0.6                         0.61
   Sensitivity                 /                         47%                       78%                        /                         80%                         82%
   Specificity                 /                         90%                       72%                        77%                       70%                         86%
   Positive predictive value   /                         65%                       32%                        62%                       54%                         70%
   Negative predictive value   /                         81%                       95%                        /                         89%                         92%
                                                                                                                                                                    
  For cirrhosis                                                                                                                                                     
   Cut-off                     0.84                      /                         0.61                       /                         0.75                        0.84
   Sensitivity                 71%                       /                         92%                        /                         86%                         100
   Specificity                 89%                       /                         72%                        /                         74%                         97%
   Positive predictive value   /                         /                         11%                        /                         37%                         89%
   Negative predictive value                             /                         100%                       /                         97%                         100
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